Maxwell Biotech Venture Fund’s Portfolio Company Infectex Acquires Exclusive Rights to Qurient’s Tuberculosis Drug Q203

Russian and Korean biotech companies Infectex, Ltd. and Qurient, Ltd. have announced a license agreement granting Infectex exclusive rights to develop and commercialize Qurient’s Tuberculosis-fighting drug Q203 in the Russian Federation, Armenia, Azerbaijan, Belarus, Kazakhstan, Kyrgyzstan, Moldova, Tajikistan, Turkmenistan, Uzbekistan  and Ukraine. Infectex is a portfolio company of Maxwell Biotech Venture Fund, created with the […]


Maxwell Biotech Venture Fund’s Portfolio Company Infectex Enrolls First Patients in Pivotal Clinical Trial of SQ109 for Multi-Drug Resistant Tuberculosis (MDR-TB)

Infectex, a Russian biotech company in Maxwell Biotech Venture Fund’s portfolio announced today enrollment of the first patients in its Phase IIb-III clinical trial of SQ109 for MDR-TB. Infectex was founded in 2011 to develop and commercialize innovative products for the treatment of TB. The study, which will be conducted at specialized clinical centers in […]


Infectex develops an innovative drug SQ109 for MDR-TB treatment

TV Center A Skolkovo resident Infectex, a portfolio company of Maxwell Biotech Venture Fund, established with the participation of RVC develops an innovative drug SQ109 for the multidrug-resistant tuberculosis (MDR-TB) treatment together with an American biotech company Sequella. Prof. Sergey Borisov, chief study coordinator, deputy director for science and clinical work at Moscow Research Center […]


Infectex Receives Russian Regulator’s Approval to Conduct Pivotal Clinical Trial for Sequella’s Antibiotic, SQ109, for Tuberculosis

SQ109 will be evaluated for efficacy on multi-drug resistant patients Infectex has recently received notification from the Russian Ministry of Health for approval to begin the pivotal clinical trial associated with a drug registration submission, and can now proceed with the clinical development of SQ109 for treatment of tuberculosis (TB) in the Russian Federation. A […]


Infectex has become a resident of the Skolkovo Foundation

A biotech company Infectex is the second portfolio company of Maxwell Biotech Venture Fund to receive the resident status in the Innovation Center of the Skolkovo Foundation. Infectex, Ltd. is a Russian innovative company, a member of the biotech holding Maxwell Biotech Group. The main activity of Infectex is aimed at development and market promotion […]